{"id":1017125,"date":"2026-11-05T03:37:48","date_gmt":"2026-11-05T08:37:48","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/immuneering-to-present-at-the-guggenheim-3rd-annual-healthcare-innovation-conference\/"},"modified":"2026-11-05T03:37:48","modified_gmt":"2026-11-05T08:37:48","slug":"immuneering-to-present-at-the-guggenheim-3rd-annual-healthcare-innovation-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/immuneering-to-present-at-the-guggenheim-3rd-annual-healthcare-innovation-conference\/","title":{"rendered":"Immuneering to Present at the Guggenheim 3rd Annual Healthcare Innovation Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">NEW YORK, Nov.  04, 2026  (GLOBE NEWSWIRE) &#8212; Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced that management will participate in a fireside chat at the Guggenheim 3rd Annual Healthcare Innovation in Boston on Monday, November 9, 2026, at 11:00 am ET. The fireside chat will be webcast live and archived in the Investor Relations section of Immuneering\u2019s website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=7U1Dh1G0xCUAnspyC4xr_eMnsO3AU6w2jrpdMyNoQM_zvYYtMeM71kzewWigVtzYKy6pY97AX84A50sqCFok-Zjs-Y_HIPUELU8Z3cMJsBuXoDq5FJ9Li4BB34Rz-2tBB-qRxZDnXgF8aDebJGx1I1mY1R9CW8F8Yip7tL7Tli3tmVqx62bi5jUF1INsVhGd\" rel=\"nofollow\" target=\"_blank\">Events &amp; Presentations | Immuneering Corporation<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>About Immuneering Corporation<\/strong><br \/>\n        <br \/>Immuneering is a late-stage clinical oncology company dedicated to keeping cancer patients alive and helping them thrive, with an initial focus on patients with RAS, RAF, and other MAPK-driven cancers. The Company is developing an entirely new category of cancer medicines, Deep Cyclic Inhibitors, designed to improve overall survival by three mechanisms: shrinking tumors durably with less resistance, preserving body mass by countering cachexia, and minimizing side effects to maximize performance status and combinability. Immuneering\u2019s lead product candidate, atebimetinib, is an oral, once-daily Deep Cyclic Inhibitor of MEK, designed to improve survival across many cancer indications. The Company is conducting a global randomized pivotal trial, MAPKeeper 301, evaluating atebimetinib in combination with chemotherapy in first-line pancreatic cancer patients. The Company\u2019s development pipeline also includes additional combination opportunities and preclinical stage programs. For more information, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=HvgNiLH9FkGWD9aTl9Kl_xMhEZZt2bdQhQUwXCpmtmcBvvpcieR_1Tlke_TMX42D7QSOZcKy3yLWySIb_srZ597VEPI8vDscnscTv-QI0fEWdTmqDBZpt7SKwt-3IpupCsaHRkNnGyFtdEdkPLIubPfCA7CN27ZM5HHQcQ8xL4k2S3Enk4svcd_RSM6nA6uaB4ZZdKf-w6Q0TzuYZa7ZaF21RxrPCoWnie22l5VghHN3RmoQ_O_A7Hl2o90Wa_jLnPiQl6ibvKClLax31QYedzuzwjcl30WKulYjwNeK97V-_XYLXt1JVNfT5BDP-5ha9fG0HbG95NaKMZ_VJjkMV-b6QWaGqQm3Y53ZR3GqSdeEI7bLAbEevh4JmXNkgvIilbP1pccbvKOE1MJV9HYoRa1znEWkjgdbRf5LuolOS1zzwt8AIKirgLqNWmX4gTw5\" rel=\"nofollow\" target=\"_blank\">www.immuneering.com<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>Investor Contact:<br \/><\/strong>Laurence Watts<br \/>New Street Investor Relations<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ipf8fIwUPG9F-AmuEQrPR4-V2NQzE6wDSTiU7SrKHTbP81m9Cn_xOdOJ3oDLiLgxcY1lvJBTPT6qengHskWd43FfUBMvIT9UfnsEmLkTYBdRoi52ltoGFGPXMK9P_MxX\" rel=\"nofollow\" target=\"_blank\">laurence@newstreetir.com<\/a>\u00a0<\/p>\n<p>\n        <strong>Media Contact:<\/strong><br \/>\n        <br \/>David Caouette<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=iQQ3xhEg49cL8nQgP33Oed5O6fX9kUUuLOCFWbqguvPaF6XKvfKezkVZ4i8fqMdn9ghOCKrpraT55Y0DOZn35DHdpevmDwbhiqOdD-0WIqYTGiSXTCsttdMADiv4OJM0\" rel=\"nofollow\" target=\"_blank\">dcaouette@immuneering.com<\/a>\u00a0<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg2OTkwOSM3OTQ0NDIyIzIyMDkzOTY=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/MTYzZDJhZjMtOWY0Yi00MTY4LTkwODMtYjlhNzg4NmU4MTJhLTEyMjA5NDktMjAyNi0xMS0wNC1lbg==\/tiny\/Immuneering-Corporation.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>NEW YORK, Nov. 04, 2026 (GLOBE NEWSWIRE) &#8212; Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced that management will participate in a fireside chat at the Guggenheim 3rd Annual Healthcare Innovation in Boston on Monday, November 9, 2026, at 11:00 am ET. The fireside chat will be webcast live and archived in the Investor Relations section of Immuneering\u2019s website at Events &amp; Presentations | Immuneering Corporation. About Immuneering Corporation Immuneering is a late-stage clinical oncology company dedicated to keeping cancer patients alive and helping them thrive, with an initial focus on patients with RAS, RAF, and other MAPK-driven cancers. The Company is developing an entirely new category &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/immuneering-to-present-at-the-guggenheim-3rd-annual-healthcare-innovation-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Immuneering to Present at the Guggenheim 3rd Annual Healthcare Innovation Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1017125","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Immuneering to Present at the Guggenheim 3rd Annual Healthcare Innovation Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/immuneering-to-present-at-the-guggenheim-3rd-annual-healthcare-innovation-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Immuneering to Present at the Guggenheim 3rd Annual Healthcare Innovation Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NEW YORK, Nov. 04, 2026 (GLOBE NEWSWIRE) &#8212; Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced that management will participate in a fireside chat at the Guggenheim 3rd Annual Healthcare Innovation in Boston on Monday, November 9, 2026, at 11:00 am ET. The fireside chat will be webcast live and archived in the Investor Relations section of Immuneering\u2019s website at Events &amp; Presentations | Immuneering Corporation. About Immuneering Corporation Immuneering is a late-stage clinical oncology company dedicated to keeping cancer patients alive and helping them thrive, with an initial focus on patients with RAS, RAF, and other MAPK-driven cancers. The Company is developing an entirely new category &hellip; Continue reading &quot;Immuneering to Present at the Guggenheim 3rd Annual Healthcare Innovation Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/immuneering-to-present-at-the-guggenheim-3rd-annual-healthcare-innovation-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-11-05T08:37:48+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg2OTkwOSM3OTQ0NDIyIzIyMDkzOTY=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immuneering-to-present-at-the-guggenheim-3rd-annual-healthcare-innovation-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immuneering-to-present-at-the-guggenheim-3rd-annual-healthcare-innovation-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Immuneering to Present at the Guggenheim 3rd Annual Healthcare Innovation Conference\",\"datePublished\":\"2026-11-05T08:37:48+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immuneering-to-present-at-the-guggenheim-3rd-annual-healthcare-innovation-conference\\\/\"},\"wordCount\":245,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immuneering-to-present-at-the-guggenheim-3rd-annual-healthcare-innovation-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg2OTkwOSM3OTQ0NDIyIzIyMDkzOTY=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immuneering-to-present-at-the-guggenheim-3rd-annual-healthcare-innovation-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immuneering-to-present-at-the-guggenheim-3rd-annual-healthcare-innovation-conference\\\/\",\"name\":\"Immuneering to Present at the Guggenheim 3rd Annual Healthcare Innovation Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immuneering-to-present-at-the-guggenheim-3rd-annual-healthcare-innovation-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immuneering-to-present-at-the-guggenheim-3rd-annual-healthcare-innovation-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg2OTkwOSM3OTQ0NDIyIzIyMDkzOTY=\",\"datePublished\":\"2026-11-05T08:37:48+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immuneering-to-present-at-the-guggenheim-3rd-annual-healthcare-innovation-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immuneering-to-present-at-the-guggenheim-3rd-annual-healthcare-innovation-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immuneering-to-present-at-the-guggenheim-3rd-annual-healthcare-innovation-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg2OTkwOSM3OTQ0NDIyIzIyMDkzOTY=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg2OTkwOSM3OTQ0NDIyIzIyMDkzOTY=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immuneering-to-present-at-the-guggenheim-3rd-annual-healthcare-innovation-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Immuneering to Present at the Guggenheim 3rd Annual Healthcare Innovation Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Immuneering to Present at the Guggenheim 3rd Annual Healthcare Innovation Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/immuneering-to-present-at-the-guggenheim-3rd-annual-healthcare-innovation-conference\/","og_locale":"en_US","og_type":"article","og_title":"Immuneering to Present at the Guggenheim 3rd Annual Healthcare Innovation Conference - Market Newsdesk","og_description":"NEW YORK, Nov. 04, 2026 (GLOBE NEWSWIRE) &#8212; Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced that management will participate in a fireside chat at the Guggenheim 3rd Annual Healthcare Innovation in Boston on Monday, November 9, 2026, at 11:00 am ET. The fireside chat will be webcast live and archived in the Investor Relations section of Immuneering\u2019s website at Events &amp; Presentations | Immuneering Corporation. About Immuneering Corporation Immuneering is a late-stage clinical oncology company dedicated to keeping cancer patients alive and helping them thrive, with an initial focus on patients with RAS, RAF, and other MAPK-driven cancers. The Company is developing an entirely new category &hellip; Continue reading \"Immuneering to Present at the Guggenheim 3rd Annual Healthcare Innovation Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/immuneering-to-present-at-the-guggenheim-3rd-annual-healthcare-innovation-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2026-11-05T08:37:48+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg2OTkwOSM3OTQ0NDIyIzIyMDkzOTY=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immuneering-to-present-at-the-guggenheim-3rd-annual-healthcare-innovation-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immuneering-to-present-at-the-guggenheim-3rd-annual-healthcare-innovation-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Immuneering to Present at the Guggenheim 3rd Annual Healthcare Innovation Conference","datePublished":"2026-11-05T08:37:48+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immuneering-to-present-at-the-guggenheim-3rd-annual-healthcare-innovation-conference\/"},"wordCount":245,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immuneering-to-present-at-the-guggenheim-3rd-annual-healthcare-innovation-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg2OTkwOSM3OTQ0NDIyIzIyMDkzOTY=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immuneering-to-present-at-the-guggenheim-3rd-annual-healthcare-innovation-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/immuneering-to-present-at-the-guggenheim-3rd-annual-healthcare-innovation-conference\/","name":"Immuneering to Present at the Guggenheim 3rd Annual Healthcare Innovation Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immuneering-to-present-at-the-guggenheim-3rd-annual-healthcare-innovation-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immuneering-to-present-at-the-guggenheim-3rd-annual-healthcare-innovation-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg2OTkwOSM3OTQ0NDIyIzIyMDkzOTY=","datePublished":"2026-11-05T08:37:48+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immuneering-to-present-at-the-guggenheim-3rd-annual-healthcare-innovation-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/immuneering-to-present-at-the-guggenheim-3rd-annual-healthcare-innovation-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immuneering-to-present-at-the-guggenheim-3rd-annual-healthcare-innovation-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg2OTkwOSM3OTQ0NDIyIzIyMDkzOTY=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg2OTkwOSM3OTQ0NDIyIzIyMDkzOTY="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immuneering-to-present-at-the-guggenheim-3rd-annual-healthcare-innovation-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Immuneering to Present at the Guggenheim 3rd Annual Healthcare Innovation Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1017125","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1017125"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1017125\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1017125"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1017125"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1017125"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}